Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Review

The role of death-associated protein 3 in apoptosis, anoikis and human cancer

Authors: Umar Wazir, Mona MAW Orakzai, Zubair S Khanzada, Wen G Jiang, Anup K Sharma, Abdul Kasem, Kefah Mokbel

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Death-associated protein 3 (DAP3) is a molecule with a significant role in the control of both apoptosis and anoikis. Apoptosis is the predominant type of programmed cell death (PCD) which may occur in response to irreparable damage to DNA, or in response to induction by inflammatory cells. Anoikis is subset of apoptosis which occurs in epithelial cells in response to detachment from the surrounding matrix. Both apoptosis and anoikis are of interest in the context of carcinogenesis. In this review, we shall discuss apoptosis and anoikis, and the recent literature regarding the role of DAP3 in both these pathways.
Literature
1.
2.
3.
GlÜCksmann A. Cell deaths in normal vertebrate ontogeny. Biol Rev. 1951;26(1):59–86. doi:10.1111/j.1469-185X.1951.tb00774.x.CrossRefPubMed
4.
Kerr JF. Shrinkage necrosis: a distinct mode of cellular death. J Pathol. 1971;105(1):13–20. doi:10.1002/path.1711050103.CrossRefPubMed
5.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.CrossRefPubMedCentralPubMed
6.
Formigli L, Papucci L, Tani A, Schiavone N, Tempestini A, Orlandini GE, et al. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol. 2000;182(1):41–9. doi:10.1002/(SICI)1097-4652(200001)182:1 < 41::AID-JCP5 > 3.0.CO;2-7.CrossRefPubMed
7.
Papucci L, Formigli L, Schiavone N, Tani A, Donnini M, Lapucci A, et al. Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression. Cell Tissue Res. 2004;316(2):197–209.doi:10.1007/s00441-004-0872-z.CrossRefPubMed
8.
Leist M. Intracellular Adenosine Triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med. 1997;185(8):1481–6. doi:10.1084/jem.185.8.1481.CrossRefPubMedCentralPubMed
9.
Chang C, Simmons DT, Martin MA, Mora PT. Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol. 1979;31(2):463–71.PubMedCentralPubMed
10.
Kress M, May E, Cassingena R, May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol. 1979;31(2):472–83.PubMedCentralPubMed
11.
May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 1999;18(53):7621–36. doi:10.1038/sj.onc.1203285.CrossRefPubMed
12.
Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984;4(9):1689–94.PubMedCentralPubMed
13.
DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A. 1979;76(5):2420–4.CrossRefPubMedCentralPubMed
14.
Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4(12):1099–109.CrossRefPubMed
15.
16.
Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619–26.CrossRefPubMed
17.
Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med. 2010;31(2):205–14. doi:10.1016/j.mam.2010.02.001.CrossRefPubMedCentralPubMed
18.
Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532–42. doi:10.1038/nri2115.CrossRefPubMed
19.
Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, et al. Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis. Proc Natl Acad Sci U S A. 2003;100(9):5211–6. doi:10.1073/pnas.0431215100.CrossRefPubMedCentralPubMed
20.
Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol. 2001;152(3):633–43.CrossRefPubMedCentralPubMed
21.
Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002;21(17):4520–30.CrossRefPubMedCentralPubMed
22.
Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001;276(49):46639–46. doi:10.1074/jbc.M105102200.CrossRefPubMed
23.
Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84(2):299–308.CrossRefPubMed
24.
Kissil JL, Kimchi A. Assignment of death associated protein 3 (DAP3) to human chromosome 1q21 by in situ hybridization. Cytogenet Cell Genet. 1997;77(3–4):252.CrossRefPubMed
25.
Miyazaki T, Shen M, Fujikura D, Tosa N, Kim HR, Kon S, et al. Functional role of death-associated protein 3 (DAP3) in anoikis. J Biol Chem. 2004;279(43):44667–72. doi:10.1074/jbc.M408101200.CrossRefPubMed
26.
Harada T, Iwai A, Miyazaki T. Identification of DELE, a novel DAP3-binding protein which is crucial for death receptor-mediated apoptosis induction. Apoptosis. 2010;15(10):1247–55. doi:10.1007/s10495-010-0519-3.CrossRefPubMed
27.
Takeda S, Iwai A, Nakashima M, Fujikura D, Chiba S, Li HM, et al. LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res. 2007;27(2):761–8.PubMed
28.
Duivenvoorden WC, Beatty LK, Lhotak S, Hill B, Mak I, Paulin G, et al. Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer. 2013;108(2):327–33. doi:10.1038/bjc.2012.574.CrossRefPubMedCentralPubMed
29.
Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, Walker CL, et al. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci U S A. 2013;110(32):E2950–7. doi:10.1073/pnas.1307736110.CrossRefPubMedCentralPubMed
30.
Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47(1):19–28.CrossRefPubMed
31.
Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74(4):609–19.CrossRefPubMed
32.
Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183–92.CrossRefPubMed
33.
Shamas-Din A, Kale J, Leber B, Andrews DW. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5(4):a008714. doi:10.1101/cshperspect.a008714.CrossRefPubMedCentralPubMed
34.
Hikisz P, Kilianska ZM. PUMA, a critical mediator of cell death–one decade on from its discovery. Cell Mol Biol Lett. 2012;17(4):646–69. doi:10.2478/s11658-012-0032-5.CrossRefPubMed
35.
Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–9.CrossRefPubMed
36.
Zou H. An APAF-1 Cytochrome c Multimeric complex is a functional Apoptosome that activates Procaspase-9. J Biol Chem. 1999;274(17):11549–56. doi:10.1074/jbc.274.17.11549.CrossRefPubMed
37.
Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell. 2006;22(2):269–75. doi:10.1016/j.molcel.2006.03.009.CrossRefPubMed
38.
Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004;73:87–106. doi:10.1146/annurev.biochem.73.011303.073706.CrossRefPubMed
39.
Zhou LL, Zhou LY, Luo KQ, Chang DC. Smac/DIABLO and cytochrome c are released from mitochondria through a similar mechanism during UV-induced apoptosis. Apoptosis. 2005;10(2):289–99. doi:10.1007/s10495-005-0803-9.CrossRefPubMed
40.
Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408(6815):1008–12. doi:10.1038/35050012.CrossRefPubMed
41.
Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene. 2007;26(29):4189–98. doi:10.1038/sj.onc.1210196.CrossRefPubMed
42.
Flanagan L, Sebastia J, Tuffy LP, Spring A, Lichawska A, Devocelle M, et al. XIAP impairs Smac release from the mitochondria during apoptosis. Cell Death Dis. 2010;1:e49. doi:10.1038/cddis.2010.26.CrossRefPubMedCentralPubMed
43.
Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 2003;17(12):1487–96. doi:10.1101/gad.1097903.CrossRefPubMedCentralPubMed
44.
Vande Walle L, Van Damme P, Lamkanfi M, Saelens X, Vandekerckhove J, Gevaert K, et al. Proteome-wide Identification of HtrA2/Omi substrates. J Proteome Res. 2007;6(3):1006–15. doi:10.1021/pr060510d.CrossRefPubMed
45.
Ye H, Cande C, Stephanou NC, Jiang S, Gurbuxani S, Larochette N, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9(9):680–4. doi:10.1038/nsb836.CrossRefPubMed
46.
Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, et al. Regulation of AIF expression by p53. Cell Death Differ. 2006;13(12):2140–9. doi:10.1038/sj.cdd.4401965.CrossRefPubMed
47.
Varecha M, Potesilova M, Matula P, Kozubek M. Endonuclease G interacts with histone H2B and DNA topoisomerase II alpha during apoptosis. Mol Cell Biochem. 2012;363(1–2):301–7. doi:10.1007/s11010-011-1182-x.CrossRefPubMed
48.
Suzuki T, Terasaki M, Takemoto-Hori C, Hanada T, Ueda T, Wada A, et al. Proteomic analysis of the mammalian mitochondrial ribosome. Identification of protein components in the 28 S small subunit. J Biol Chem. 2001;276(35):33181–95. doi:10.1074/jbc.M103236200.CrossRefPubMed
49.
Kim HR, Chae HJ, Thomas M, Miyazaki T, Monosov A, Monosov E, et al. Mammalian dap3 is an essential gene required for mitochondrial homeostasis in vivo and contributing to the extrinsic pathway for apoptosis. FASEB J. 2007;21(1):188–96. doi:10.1096/fj.06-6283com.CrossRefPubMed
50.
Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004;304(5672):843–6. doi:10.1126/science.1095432.CrossRefPubMed
51.
52.
Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010;1805(2):123–40. doi:10.1016/j.bbcan.2009.11.004.PubMed
53.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17(6):1675–87. doi:10.1093/emboj/17.6.1675.CrossRefPubMedCentralPubMed
54.
Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta. 2011;1813(4):558–63. doi:10.1016/j.bbamcr.2011.01.026.CrossRefPubMed
55.
Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012;19(1):42–50. doi:10.1038/cdd.2011.121.CrossRefPubMedCentralPubMed
56.
Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A. 2008;105(35):12815–9. doi:10.1073/pnas.0707715105.CrossRefPubMedCentralPubMed
57.
Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998;391(6662):96–9. doi:10.1038/34214.CrossRefPubMed
58.
Tsuruta T, Oh-Hashi K, Ueno Y, Kitade Y, Kiuchi K, Hirata Y. RNAi knockdown of caspase-activated DNase inhibits rotenone-induced DNA fragmentation in HeLa cells. Neurochem Int. 2007;50(4):601–6. doi:10.1016/j.neuint.2006.12.002.CrossRefPubMed
59.
Denault JB, Eckelman BP, Shin H, Pop C, Salvesen GS. Caspase 3 attenuates XIAP (X-linked inhibitor of apoptosis protein)-mediated inhibition of caspase 9. Biochem J. 2007;405(1):11–9. doi:10.1042/BJ20070288.PubMedCentralPubMed
60.
Boccellino M, Giuberti G, Quagliuolo L, Marra M, D’Alessandro AM, Fujita H, et al. Apoptosis induced by interferon-alpha and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. J Cell Physiol. 2004;201(1):71–83. doi:10.1002/jcp.20058.CrossRefPubMed
61.
Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997;272(42):26159–65.CrossRefPubMed
62.
Mandal D, Mazumder A, Das P, Kundu M, Basu J. Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes. J Biol Chem. 2005;280(47):39460–7. doi:10.1074/jbc.M506928200.CrossRefPubMed
63.
Mintzer R, Ramaswamy S, Shah K, Hannoush RN, Pozniak CD, Cohen F, et al. A whole cell assay to measure caspase-6 activity by detecting cleavage of lamin A/C. PLoS One. 2012;7(1):e30376. doi:10.1371/journal.pone.0030376.CrossRefPubMedCentralPubMed
64.
65.
Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14(1):10–22. doi:10.1038/sj.cdd.4402038.CrossRefPubMed
66.
Vigano E, Mortellaro A. Caspase-11: the driving factor for noncanonical inflammasomes. Eur J Immunol. 2013;43(9):2240–5. doi:10.1002/eji.201343800.CrossRefPubMed
67.
Nickles D, Falschlehner C, Metzig M, Boutros M. A genome-wide RNA interference screen identifies caspase 4 as a factor required for tumor necrosis factor alpha signaling. Mol Cell Biol. 2012;32(17):3372–81. doi:10.1128/MCB. 06739-11.CrossRefPubMedCentralPubMed
68.
Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD. Caspase-4 is required for activation of inflammasomes. J Immunol. 2012;188(4):1992–2000. doi:10.4049/jimmunol.1101620.CrossRefPubMed
69.
Yamamuro A, Kishino T, Ohshima Y, Yoshioka Y, Kimura T, Kasai A, et al. Caspase-4 directly activates caspase-9 in endoplasmic reticulum stress-induced apoptosis in SH-SY5Y cells. J Pharmacol Sci. 2011;115(2):239–43.CrossRefPubMed
70.
Li C, Wei J, Li Y, He X, Zhou Q, Yan J, et al. Transmembrane Protein 214 (TMEM214) mediates endoplasmic reticulum stress-induced caspase 4 enzyme activation and apoptosis. J Biol Chem. 2013;288(24):17908–17. doi:10.1074/jbc.M113.458836.CrossRefPubMedCentralPubMed
71.
Hitomi J, Katayama T, Eguchi Y, Kudo T, Taniguchi M, Koyama Y, et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death. J Cell Biol. 2004;165(3):347–56. doi:10.1083/jcb.200310015.CrossRefPubMedCentralPubMed
72.
Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991;173(5):1099–109.CrossRefPubMed
73.
Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003;112(5):659–72.CrossRefPubMed
74.
75.
Trapani JA. Granzymes, cytotoxic granules and cell death: the early work of Dr. Jurg Tschopp. Cell Death Differ. 2012;19(1):21–7. doi:10.1038/cdd.2011.156.CrossRefPubMedCentralPubMed
76.
Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol. 2008;76(11):1352–64. doi:10.1016/j.bcp.2008.07.023.CrossRefPubMed
77.
78.
Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol. 1998;143(2):547–60.CrossRefPubMedCentralPubMed
79.
Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. Science. 1997;276(5317):1425–8.CrossRefPubMed
80.
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003;278(21):18811–6. doi:10.1074/jbc.M301010200.CrossRefPubMed
81.
Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E. The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol Biol Cell. 2000;11(3):1103–12.CrossRefPubMedCentralPubMed
82.
Puthalakath H, Villunger A, O’Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001;293(5536):1829–32. doi:10.1126/science.1062257.CrossRefPubMed
83.
Idogawa M, Adachi M, Minami T, Yasui H, Imai K. Overexpression of BAD preferentially augments anoikis. Int J Canc Suppl J Int Canc Suppl. 2003;107(2):215–23. doi:10.1002/ijc.11399.CrossRef
84.
Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol. 2003;5(8):733–40. doi:10.1038/ncb1026.CrossRefPubMed
85.
Frisch SM. Evidence for a function of death-receptor-related, death-domain-containing proteins in anoikis. Curr Biol. 1999;9(18):1047–9.CrossRefPubMed
86.
Grossmann J, Walther K, Artinger M, Kiessling S, Scholmerich J. Apoptotic signaling during initiation of detachment-induced apoptosis (“anoikis”) of primary human intestinal epithelial cells. Cell Growth Differ. 2001;12(3):147–55.PubMed
87.
Walker TN, Cimakasky LM, Coleman EM, Madison MN, Hildreth JE. Antibody against integrin lymphocyte function-associated antigen 1 inhibits HIV type 1 infection in primary cells through caspase-8-mediated apoptosis. AIDS Res Hum Retroviruses. 2013;29(2):371–83. doi:10.1089/AID.2011.0395.PubMedCentralPubMed
88.
Fanucchi S, Veale RB. Delayed caspase-8 activation and enhanced integrin beta1-activated FAK underpins anoikis in oesophageal carcinoma cells harbouring mt p 53–R175H. Cell Biol Int. 2011;35(8):819–26. doi:10.1042/CBI20100894.CrossRefPubMed
89.
Lauricella M, Ciraolo A, Carlisi D, Vento R, Tesoriere G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie. 2012;94(2):287–99. doi:10.1016/j.biochi.2011.06.031.CrossRefPubMed
90.
Estrugo D, Fischer A, Hess F, Scherthan H, Belka C, Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One. 2007;2(3):e269. doi:10.1371/journal.pone.0000269.CrossRefPubMedCentralPubMed
91.
Li HM, Fujikura D, Harada T, Uehara J, Kawai T, Akira S, et al. IPS-1 is crucial for DAP3-mediated anoikis induction by caspase-8 activation. Cell Death Differ. 2009;16(12):1615–21. doi:10.1038/cdd.2009.97.CrossRefPubMed
92.
Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Kaczmarek E, Ponce F, et al. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clinical Canc Res. 2001;7(8):2480–9.
93.
Wazir U, Jiang WG, Sharma AK, Mokbel K. The mRNA expression of DAP3 in human breast cancer: correlation with clinicopathological parameters. Anticancer Res. 2012;32(2):671–4.PubMed
94.
Wazir U, Sanders AJ, Wazir AM, Ye L, Jiang WG, Ster IC, et al. Effects of the knockdown of death-associated protein 3 expression on cell adhesion, growth and migration in breast cancer cells. Oncol Rep. 2015;33(5):2575–82. doi:10.3892/or.2015.3825.PubMed
Metadata
Title
The role of death-associated protein 3 in apoptosis, anoikis and human cancer
Authors
Umar Wazir
Mona MAW Orakzai
Zubair S Khanzada
Wen G Jiang
Anup K Sharma
Abdul Kasem
Kefah Mokbel
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0187-z

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

Adenovirus-mediated co-expression of the TRAIL and HN genes inhibits growth and induces apoptosis in Marek’s disease tumor cell line MSB-1

Primary research

Arf6 regulates EGF-induced internalization of E-cadherin in breast cancer cells

Erratum

Erratum to: Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity

Review Article

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity

Primary research

The effects of MOTILIPERM on cisplatin induced testicular toxicity in Sprague–Dawley rats

Primary research

RETRACTED ARTICLE: Down-regulation of miR-133a and miR-539 are associated with unfavorable prognosis in patients suffering from osteosarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits